The great immune escape: understanding the divergent immune response in breast cancer subtypes

SS Onkar, NM Carleton, PC Lucas, TC Bruno, AV Lee… - Cancer discovery, 2023 - AACR
Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

[HTML][HTML] Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

K Van Baelen, T Geukens, M Maetens… - Annals of …, 2022 - Elsevier
Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

L Voorwerk, OI Isaeva, HM Horlings, S Balduzzi… - Nature Cancer, 2023 - nature.com
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer
subtype, but ILC-specific trials are lacking. Translational research revealed an immune …

Molecular, cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research

BL Witt, TO Tollefsbol - Life, 2023 - mdpi.com
Breast cancer comprises about 30% of all new female cancers each year and is the most
common malignant cancer in women in the United States. Breast cancer cell lines have …

Glucocorticoid receptor activation in lobular breast cancer is associated with reduced cell proliferation and promotion of metastases

BA Porter, C Frerich, M Lainé, AB Clark, I Durdana… - Cancers, 2023 - mdpi.com
Simple Summary Early-stage invasive lobular breast cancer (ILC) is characterized by
multifocal tumor growth in the breast and a distinct pattern of late metastatic spread to other …

Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer

J Alexander, K Schipper, S Nash, R Brough… - British Journal of …, 2024 - nature.com
Abstract Background Invasive Lobular Carcinoma (ILC) is a morphologically distinct breast
cancer subtype that represents up to 15% of all breast cancers. Compared to Invasive Breast …

[HTML][HTML] In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy

GJ Cheng, EY Leung, DC Singleton - Exploration of Targeted Anti …, 2022 - ncbi.nlm.nih.gov
The development of endocrine resistance is a common reason for the failure of endocrine
therapies in hormone receptor-positive breast cancer. This review provides an overview of …

Sprouty genes regulate activated fibroblasts in mammary epithelial development and breast cancer

J Li, R Ma, X Wang, Y Lu, J Chen, D Feng, J Zhou… - Cell Death & …, 2024 - nature.com
Stromal fibroblasts are a major stem cell niche component essential for organ formation and
cancer development. Fibroblast heterogeneity, as revealed by recent advances in single-cell …

Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer

E Toska - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2024 - Elsevier
Abstract Estrogen receptor-positive (ER+) breast cancer is the most frequent breast cancer
subtype. Agents targeting the ER signaling pathway have been successful in reducing …

Is there a special role for ovarian hormones in the pathogenesis of lobular carcinoma?

RL Flaherty, G Sflomos, C Brisken - Endocrinology, 2024 - academic.oup.com
Lobular carcinoma represent the most common special histological subtype of breast
cancer, with the majority classed as hormone receptor-positive. Rates of invasive lobular …